Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging-Reference-Cited by-同舟云学术

Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging

Published:2020-05 Issue: Volume:89 Page:12-23
ISSN:0197-4580
Container-title:Neurobiology of Aging
language:en
Short-container-title:Neurobiology of Aging

Author:

Lietzau Grazyna,Magni Giulia,Kehr Jan,Yoshitake Takashi,Candeias Emanuel,Duarte Ana I.,Pettersson Hans,Skogsberg Josefin,Abbracchio Maria P.,Klein Thomas,Nyström Thomas,Ceruti Stefania,Darsalia Vladimer^ORCID,Patrone Cesare^ORCID

Funder

EFSD

Swedish Research Council

Swedish Heart-Lung Foundation

Diabetesfonden, Karolinska Institutet

Publisher

Elsevier BV

Subject

Geriatrics and Gerontology,Developmental Biology,Clinical Neurology,Ageing,General Neuroscience

Reference72 articles.

1. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial;Athauda;Lancet,2017

2. Is exenatide a treatment for Parkinson's disease?;Athauda;J. Parkinsons Dis.,2017